193 related articles for article (PubMed ID: 30370408)
1. Prognostic significance of receptor for hyaluronan acid-mediated motility (CD168) in acute pediatric leukemias - assessment of clinical outcome, post induction, end of treatment and minimal residual disease.
Shalini CNS; Suman FR; Jacob JS; Rajendran R; Scott JX; Latha MS
Hematol Transfus Cell Ther; 2018; 40(4):310-316. PubMed ID: 30370408
[TBL] [Abstract][Full Text] [Related]
2. In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival.
Tzankov A; Strasser U; Dirnhofer S; Menter T; Arber C; Jotterand M; Rovo A; Tichelli A; Stauder R; Günthert U
Ann Hematol; 2011 Aug; 90(8):901-9. PubMed ID: 21274712
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.
Greiner J; Li L; Ringhoffer M; Barth TF; Giannopoulos K; Guillaume P; Ritter G; Wiesneth M; Döhner H; Schmitt M
Blood; 2005 Aug; 106(3):938-45. PubMed ID: 15827130
[TBL] [Abstract][Full Text] [Related]
4. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.
Snauwaert S; Vanhee S; Goetgeluk G; Verstichel G; Van Caeneghem Y; Velghe I; Philippé J; Berneman ZN; Plum J; Taghon T; Leclercq G; Thielemans K; Kerre T; Vandekerckhove B
Haematologica; 2012 Oct; 97(10):1539-47. PubMed ID: 22532518
[TBL] [Abstract][Full Text] [Related]
5. Frequency of expression of RHAMM/CD168 in Egyptian patients with CML.
Gouda HM; Abdel Mohsen MM
J Egypt Natl Canc Inst; 2009 Jun; 21(2):93-9. PubMed ID: 21057560
[TBL] [Abstract][Full Text] [Related]
6. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.
Greiner J; Ringhoffer M; Taniguchi M; Schmitt A; Kirchner D; Krähn G; Heilmann V; Gschwend J; Bergmann L; Döhner H; Schmitt M
Exp Hematol; 2002 Sep; 30(9):1029-35. PubMed ID: 12225794
[TBL] [Abstract][Full Text] [Related]
7. The Receptor for Hyaluronan-Mediated Motility (CD168) promotes inflammation and fibrosis after acute lung injury.
Cui Z; Liao J; Cheong N; Longoria C; Cao G; DeLisser HM; Savani RC
Matrix Biol; 2019 May; 78-79():255-271. PubMed ID: 30098420
[TBL] [Abstract][Full Text] [Related]
8. The Role of CD44 and RHAMM in Endometrial (Endometrioid Type) Cancer: An Immunohistochemical Study.
Klarić M; Haller H; Brnčić Fischer A; Babarović E; Prijić A; Eminović S
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):606-612. PubMed ID: 29734248
[TBL] [Abstract][Full Text] [Related]
9. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells.
Hamilton SR; Fard SF; Paiwand FF; Tolg C; Veiseh M; Wang C; McCarthy JB; Bissell MJ; Koropatnick J; Turley EA
J Biol Chem; 2007 Jun; 282(22):16667-80. PubMed ID: 17392272
[TBL] [Abstract][Full Text] [Related]
10. Immune responses to RHAMM in patients with acute myeloid leukemia after chemotherapy and allogeneic stem cell transplantation.
Casalegno-Garduño R; Meier C; Schmitt A; Spitschak A; Hilgendorf I; Rohde S; Hirt C; Freund M; Pützer BM; Schmitt M
Clin Dev Immunol; 2012; 2012():146463. PubMed ID: 22719778
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.
Li L; Reinhardt P; Schmitt A; Barth TF; Greiner J; Ringhoffer M; Döhner H; Wiesneth M; Schmitt M
Cancer Immunol Immunother; 2005 Jul; 54(7):685-93. PubMed ID: 15627212
[TBL] [Abstract][Full Text] [Related]
12. Post-chemotherapy Changes in Bone Marrow in Acute Leukemia With Emphasis on Detection of Residual Disease by Immunohistochemistry.
Ayyanar P; Kar R; Dubashi B; Basu D
Cureus; 2021 Dec; 13(12):e20175. PubMed ID: 35004001
[TBL] [Abstract][Full Text] [Related]
13. Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers.
Koelzer VH; Huber B; Mele V; Iezzi G; Trippel M; Karamitopoulou E; Zlobec I; Lugli A
Hum Pathol; 2015 Nov; 46(11):1573-81. PubMed ID: 26351067
[TBL] [Abstract][Full Text] [Related]
14. Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer.
Augustin F; Fiegl M; Schmid T; Pomme G; Sterlacci W; Tzankov A
J Clin Pathol; 2015 May; 68(5):368-73. PubMed ID: 25731190
[TBL] [Abstract][Full Text] [Related]
15. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.
Ollila TA; Olszewski AJ; Butera JN; Quesenberry MI; Quesenberry PJ; Reagan JL
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):204-209. PubMed ID: 29433979
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of CD168 expression in gastric cancer.
Ishigami S; Ueno S; Nishizono Y; Matsumoto M; Kurahara H; Arigami T; Uchikado Y; Setoyama T; Arima H; Yoshiaki K; Kijima Y; Kitazono M; Natsugoe S
BMC Cancer; 2011 Mar; 11():106. PubMed ID: 21435222
[TBL] [Abstract][Full Text] [Related]
17. Receptor for hyaluronan-mediated motility (RHAMM) defines an invasive niche associated with tumor progression and predicts poor outcomes in breast cancer patients.
Tarullo SE; He Y; Daughters C; Knutson TP; Henzler CM; Price MA; Shanley R; Witschen P; Tolg C; Kaspar RE; Hallstrom C; Gittsovich L; Sulciner ML; Zhang X; Forster CL; Lange CA; Shats O; Desler M; Cowan KH; Yee D; Schwertfeger KL; Turley EA; McCarthy JB; Nelson AC
J Pathol; 2023 Jul; 260(3):289-303. PubMed ID: 37186300
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Short NJ; Kantarjian HM; Sasaki K; Cortes JE; Ravandi F; Thomas DA; Garcia-Manero G; Khouri I; Kebriaei P; Champlin RE; Pierce S; Issa GC; Konopleva M; Kadia TM; Bueso-Ramos C; Khoury JD; Jain N; O'Brien SM; Jabbour E
Cancer; 2016 Dec; 122(24):3812-3820. PubMed ID: 27508525
[TBL] [Abstract][Full Text] [Related]
19. Blast Percentage of Bone Marrow Aspirate on Day 14 of Induction Chemotherapy Predicts Adult Acute Lymphoblastic Leukemia Treatment Outcomes.
Park HS; Kim DY; Choi EJ; Lee JH; Lee JH; Jeon M; Kang YA; Lee YS; Seol M; Cho YU; Jang S; Chi HS; Lee KH; Park CJ
Acta Haematol; 2018; 139(4):220-227. PubMed ID: 29860259
[TBL] [Abstract][Full Text] [Related]
20. The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.
Willemen Y; Van den Bergh JM; Bonte SM; Anguille S; Heirman C; Stein BM; Goossens H; Kerre T; Thielemans K; Peeters M; Van Tendeloo VF; Smits EL; Berneman ZN
Oncotarget; 2016 Nov; 7(45):73960-73970. PubMed ID: 27659531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
